3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
2
Head & Neck
2
Thoracic
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Melanoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Docetaxel
69
pembrolizumab
48
Prednisone
43
Nivolumab
40
enzalutamide
38
Gemcitabine
37
Sunitinib
36
Cyclophosphamide
29
Radiotherapy
26
Magnetic Resonance Spectroscopy
26
Leuprolide
25
Abiraterone Acetate
25
Sorafenib
23
Everolimus
23
Cisplatin
23
bicalutamide
19
atezolizumab
18
Carboplatin
18
Bevacizumab
18
avelumab
17
Radiosurgery
17
Goserelin
17
Interleukin-2
16
abiraterone
15
fludarabine
14
Doxorubicin
14
olaparib
13
durvalumab
13
cabozantinib
13
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
utomilumab
×
Genitourinary
×
Clear all
NCT02554812
2024-07-30
JAVELIN Medley
Pfizer
Phase 1/2
Terminated
409 enrolled
108 charts